<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14913">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01852708</url>
  </required_header>
  <id_info>
    <org_study_id>12-014-NPT</org_study_id>
    <nct_id>NCT01852708</nct_id>
  </id_info>
  <brief_title>Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood</brief_title>
  <official_title>Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Natera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Natera, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect maternal blood samples from pregnant women carrying
      a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including
      microdeletions in order to further develop a non-invasive prenatal screening test based on
      fetal DNA isolated from maternal blood.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Sensitivity and Specificity of the test to diagnose microdeletions (eg. 22q and 5p-) and aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Trisomy 21</condition>
  <condition>Trisomy 18</condition>
  <condition>Trisomy 13</condition>
  <condition>Sex Chromosome Abnormalities</condition>
  <condition>Microdeletion Syndromes</condition>
  <arm_group>
    <arm_group_label>Pregnant Women</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older at enrollment

          -  Singleton pregnancy

          -  Fetus with confirmed diagnosis of chromosomal abnormality or genetic disorder through
             karyotype, FISH or positive microarray results after amniocentesis or chorionic
             villus testing

          -  The biological father of the fetus at least 18 years of age

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Women carrying multiples

          -  Pregnancy is a result of IVF with pre-implantation genetic diagnosis

          -  Surrogate/egg or sperm donor used

          -  Previous participation in this study during a previous pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melissa Savage</last_name>
    <phone>650-249-9090</phone>
    <phone_ext>x411</phone_ext>
    <email>research@natera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Natera, Inc.</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zachary Demko, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>May 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Sex Chromosome Aberrations</mesh_term>
    <mesh_term>Trisomy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
